Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exercise and CFTR Modulators in Children with Cystic Fibrosis
NCT04415268Withdrawn
- Sponsor
- Universidad Europea de Madrid
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lumacaftor + ivacaftor and tezacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Universidad Europea de Madrid. Primary endpoints: Change in Strength at 16 weeks and Change in Cardiorespiratory Fitness at 16 weeks. Planned start Jun 2020; status: withdrawn.
02
Drugs
lumacaftor + ivacaftortezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04415268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04415268.